Home › Companies › KOD

Kodiak Sciences

Market cap $6.33B 65.4M shares (10-Q, Nov 9, 2026) × $96.80 close Nov 17, 2026

Most recent annual filing: 2026-03-31

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. KSI-101 Ph3 toplineDec 2026KSI-101 Ph3 topline, Dec 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Technology platforms

ABC Platform

Antibody Biopolymer Conjugate (ABC) platform — a proprietary drug delivery technology pairing free protein for immediate disease control with antibody conjugated to a high-molecular-weight biopolymer for extended ocular half-life and durability; used to develop retinal medicine candidates including Zenkuda and tabirafusp-ted

Targets: VEGF, IL-6

ABCD Platform

Antibody Biopolymer Conjugate Drug platform extending ABC to embed small molecule APIs into the biopolymer backbone for high drug-antibody ratio medicines; advancing duet programs for glaucoma (NLRP3 inhibitor + IOP-lowering molecule) and geographic atrophy (complement inhibitor + NLRP3 inhibitor); focus on ophthalmic and systemic multifactorial diseases.

Targets: NLRP3

VETi

Visual Engagement Technology and Imager — AI- and machine-learning-enabled wearable headset digital health platform with applications in retina care, identity security and cognitive sciences.

ABC

Antibody Biopolymer Conjugate platform — merges protein-based and chemistry-based therapies via molecular engineering; enables extended ocular half-life and durability for retinal vascular disease therapies including wet AMD, DR, RVO, DME, and MESI

Targets: VEGF, IL-6

ABCD

Antibody Biopolymer Conjugate Drug platform — extension of ABC platform enabling high drug-antibody ratio conjugation of small molecule APIs into the biopolymer backbone for sustained, multi-specific modulation; focus on ophthalmic diseases including glaucoma and geographic atrophy

Targets: NLRP3, complement pathway

Capital (as filed)

Cash
$88.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$43.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$88.7M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Kodiak Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Kodiak Sciences (KOD): Scientific Deep Dive for Lead and Pipeline Products Dilution risk is off the table for ~18 months and Baker Bros. insider buying is the tie-breaker, but the binary clinical risk warrants only a watch-list stance sized for a speculative position.
  2. Hold UPDATE: Kodiak Sciences (KOD) - The Franken-Formulation Gets Vindicated (and a New Name) GLOW2 validated the commercial formulation with clean safety, but after the stock doubled the risk-management call is to take principal off the table and let the rest ride into the Q3 DAYBREAK readout.
  3. Hold UPDATE: Kodiak Sciences (KOD) - The Going Concern Footnote Nobody is Reading Going-concern disclosure signals an imminent dilutive raise before the September DAYBREAK readout; the science is intact but the balance sheet is the new bear case, so hold house money and size any remaining position as a binary bet.
  4. Hold UPDATE: Kodiak Sciences (KOD) - They Started a Third Phase 3 With $125.9M in the Bank Cash fell to $125.9M with going-concern language intact and burn accelerating; a capital raise is imminent before or after DAYBREAK, so hold house money and size any remaining position as a binary bet on September.
  5. Hold UPDATE: Kodiak Sciences (KOD) - DAYBREAK Delivers the Six-Month Number Both DAYBREAK arms met non-inferiority and Zenkuda's safety is clean, but after a ~125% move the easy money is made; hold house money through the likely offering and into PEAK while KSI-501's IL-6 thesis remains unproven.
  6. Hold UPDATE: Kodiak Sciences (KOD) - Baker Bros. Bought the Breakout Baker Bros. buying at post-data prices (~$90) strengthens the insider signal and supports patience through the upcoming offering and into PEAK, but does not change the hold-house-money posture.
  7. Hold UPDATE: Kodiak Sciences (KOD) - The Raise Arrives as a Faucet The $350M ATM program at ~$91 removes the dilution-overhang risk on favorable terms (~6% illustrative dilution); hold house money into PEAK while gradually accumulating suits the ATM tape better than waiting for a single discounted block.
  8. Hold UPDATE: Kodiak Sciences (KOD) - The Faucet Is Running First ATM draw of $68.9M at ~$100/share improves the treasury with minimal dilution, but ALTO's primary endpoint was lowered to non-inferiority and the AI-guided dosing label risk is new; hold house money into PEAK as the cleanest remaining IL-6 test.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (10 quotes from 6 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)